

RESEARCH

Open Access

Anopheles gambiae salivary protein expression modulated by wild *Plasmodium falciparum* infection: highlighting of new antigenic peptides as candidates of *An. gambiae* bites

Alexandra Marie^{1*}, Philippe Holzmüller², Majoline T Tchioffo¹, Marie Rossignol¹, Edith Demettre³, Martial Seveno³, Vincent Corbel^{1,4}, Parfait Awono-Ambéné⁵, Isabelle Morlais^{1,5}, Franck Remoue¹ and Sylvie Cornelie^{1,6*}

Abstract

Background: Malaria is the major parasitic disease worldwide caused by *Plasmodium* infection. The objective of integrated malaria control programs is to decrease malaria transmission, which needs specific tools to be accurately assessed. In areas where the transmission is low or has been substantially reduced, new complementary tools have to be developed to improve surveillance. A recent approach, based on the human antibody response to *Anopheles* salivary proteins, has been shown to be efficient in evaluating human exposure to *Anopheles* bites. The aim of the present study was to identify new *An. gambiae* salivary proteins as potential candidate biomarkers of human exposure to *P. falciparum*-infective bites.

Methods: Experimental infections of *An. gambiae* by wild *P. falciparum* were carried out in semi-field conditions. Then a proteomic approach, combining 2D-DIGE and mass spectrometry, was used to identify the overexpressed salivary proteins in infected salivary glands compared to uninfected *An. gambiae* controls. Subsequently, a peptide design of each potential candidate was performed *in silico* and their antigenicity was tested by an epitope-mapping technique using blood from individuals exposed to *Anopheles* bites.

Results: Five salivary proteins (gSG6, gSG1b, TRIO, SG5 and long form D7) were overexpressed in the infected salivary glands. Eighteen peptides were designed from these proteins and were found antigenic in children exposed to the *Anopheles* bites. Moreover, the results showed that the presence of wild *P. falciparum* in salivary glands modulates the expression of several salivary proteins and also appeared to induce post-translational modifications.

Conclusions: This study is, to our knowledge, the first that compares the sialome of *An. gambiae* both infected and not infected by wild *P. falciparum*, making it possible to mimic the natural conditions of infection. This is a first step toward a better understanding of the close interactions between the parasite and the salivary gland of mosquitoes. In addition, these results open the way to define biomarkers of infective bites of *Anopheles*, which could, in the future, improve the estimation of malaria transmission and the evaluation of malaria vector control tools.

Keywords: *Anopheles gambiae*, Wild *Plasmodium falciparum*, Salivary proteins, Biomarker, Infective bites, Proteomic

* Correspondence: alexandra.marie@ird.fr; sylvie.cornelie@ird.fr
¹MIVEGEC (UMR IRD224 CNRS 5290 UM1-UM2), Institut de Recherche pour le développement (IRD), 911 avenue Agropolis, Montpellier cedex 5 34394, France

⁶MIVEGEC-IRD-CREC, Cotonou 01 BP4414 RP, Bénin

Full list of author information is available at the end of the article

Background

In Sub-Saharan Africa, *Anopheles gambiae* is the main vector of *Plasmodium falciparum*, the most deadly of the five human *Plasmodium* species, responsible for malaria. Over half a million deaths (627,000) occur every year, especially in children under 5 years of age, according to WHO [1]. Due to the lack of vaccines, the spread of resistance to anti-malaria drugs [2] and the difficulty in accessing drug treatment (the artemisinin-based combination therapies), vector control using Long Lasting Insecticide-treated Nets (LLIN) and/or Indoor Residual Spraying (IRS) still remains an important component of malaria prevention and control. However, the development of insecticide resistance in the main malaria vectors in Africa [3] is challenging the success of malaria vector control strategies [4,5]. In a context of malaria elimination in some areas, integrated malaria control campaigns have been implemented to reduce the malaria burden. Consequently, in these areas where transmission has substantially decreased, but also in urban settings or high-altitude areas where *Anopheles* exposure and malaria transmission can be very low, the current methods are not sufficiently sensitive to evaluate the human exposure to *Anopheles* bites and the risk of transmission. Indeed it appears difficult to obtain precise information on parasite detection and mosquito capture in these contexts so the development of appropriate tools is necessary.

One promising approach is to evaluate the real contact between the human host and the vector by measuring the human antibody (Ab) response to specific *Anopheles* salivary proteins [6]. During its blood meal, mosquitoes inject saliva into the human skin, inducing a humoral response. This concept has been validated using whole saliva extracts (WSEs) of *An. gambiae* [6] and in other hematophagous arthropods, such as *Aedes* [7-9], *Culex* [10,11], *Glossina* [12,13] and phlebotomine sand flies [14,15]. However, some salivary proteins are ubiquitous in arthropods and the response observed against WSEs could therefore reflect the exposure to numerous arthropods. For this reason, a biomarker of human exposure to bites must be directed to genus- or species-specific epitopes. Based on previous studies, the gSG6 protein has been shown to be specific to the *Anopheles* genus and immunogenic [16,17]. This protein was therefore validated as a specific biomarker of exposure to *Anopheles* bites in Burkina Faso [18,19] and Tanzania [20].

To optimize the specificity and the utility of the biomarker, a peptide design of this protein was performed. The gSG6-P1 peptide has been found to be antigenic and the Ab response to this peptide was positively associated with the level of exposure to *Anopheles* bites [21]. This peptide has also been validated as a biomarker in different malaria transmission areas such as rural low

exposure in Senegal [22,23], in highland areas in Kenya [24], in urban settings [25] and for exposure to *An. funestus* [26]. The limitation of this biomarker is that the Ab response to the gSG6 protein and the gSG6-P1 peptide may not discriminate between infective and non-infective bites, hence limiting the estimation of malaria transmission intensity. Settings of malaria transmission could be very different depending on field conditions, from unstable to stable malaria, with sporozoite rates ranging from 0.1% to 8% [27,28]. In low-transmission areas, the exposure to all *Anopheles* bites does not accurately represent the malaria transmission risk [29]. Moreover, hotspots of malaria transmission exist in all epidemiological settings, maintaining transmission in low-transmission seasons and fueling transmission in high-transmission seasons; the detection of these hotspots will make it possible to concentrate the integrated malaria controls [30]. Consequently, a new biomarker specific to infective bites has to be developed to assess precisely malaria risk in these particular settings and could also be useful for evaluating the efficacy of malaria control tools (drug treatments and vector controls).

The salivary glands are the crucial organ for the development and transmission of the parasite to a host. *Plasmodium* interacts with salivary proteins to enter salivary glands [31-34]. To survive and multiply in this organ, parasites have to counteract the immune system and use the vector's metabolism by modifying salivary protein expression [35]. Saliva is also essential for the success of blood-feeding [36], and consequently, the modification of salivary protein expression could promote parasite development and transmission. Rossignol et al., have demonstrated for the first time that the *Plasmodium* infection in mosquitoes decreased the expression of a salivary protein, the apyrase enzyme [37]. Transcriptomic studies have shown that genes encoding for salivary proteins were up- or down-regulated in *Ixodes scapularis* nymphs infected by flavivirus [38], *Rhipicephalus microplus* infected by *Anaplasma marginale* [39], *Culex quinquefasciatus* infected by West Nile virus [40] and *Aedes aegypti* infected by different serotypes of dengue virus (DENV) [41]. Proteomic analyses have indicated that salivary proteins were modulated in *Glossina pallipides* infected by salivary gland hypertrophy virus [42], *Ae. aegypti* infected by DENV serotype 2 (DENV-2) [43], *Ae. albopictus* infected by DENV-2 [44] and *Ae. aegypti* infected by chikungunya virus (CHIKV) [45]. As for *Plasmodium* parasites, several studies have investigated the change of salivary protein expression in *An. gambiae* and *An. stephensi* infected by murine *Plasmodium* [46-49]. The iTRAQ technique, used by Choumet et al., showed that the expression of five salivary proteins was modulated, with the ratio between infected versus non-infected salivary gland varying from 0.65 to 1.97 [46]. In a more recent study using

the 2D-PAGE method, seven salivary proteins were shown with a modulated expression in the presence of *Plasmodium berghei* varying from 0.28 to 12 [47]. The present study aimed to identify salivary proteins as potential biomarkers of *An. gambiae* infective bites. To mimic field conditions and thereby evaluate salivary protein modulation as accurately as possible, experiments were conducted in semi-field conditions. *An. gambiae* mosquitoes were fed through membrane on blood containing *P. falciparum* gametocytes from naturally infected donors. Comparison of sialome in *P. falciparum*-infected versus non-infected salivary glands of *An. gambiae* was achieved by 2D-Differential Gel Electrophoresis (2D-DIGE) and mass spectrometry (LC-MS/MS). Peptides were designed from protein candidates and their immunogenicity was tested in sera from humans living in malaria areas. These methods allowed us to select immunogenic peptides which could represent potential candidate biomarkers of *An. gambiae* infective bites.

Methods

Ethics statements

Experimental infections involving human subjects were approved by the Cameroonian National Ethical Committee (statement 099/CNE/SE/09). Children identified as gametocyte carriers were enrolled as volunteers after their parents or legal guardians had signed an informed consent form. Collection of human blood on filter papers was approved by the National Ethics Committee of the Senegal Ministry of Health (October 2008; 0084/MSP/DS/CNRS, ClinicalTrials.gov ID: NCT01545115). Oral and written informed consent was obtained from the children's parents or legal guardians.

Mosquito strain

The Kisumu strain of *An. gambiae* mosquitoes was reared in the insectary at the OCEAC (Yaounde, Cameroon). Adult mosquitoes were maintained in controlled conditions ($27 \pm 2^\circ\text{C}$, $85 \pm 5\%$ RH, and 12 h light/dark) and provided with a 6% sterile sucrose solution.

Experimental infections

Female mosquitoes were fed on *P. falciparum* gametocyte carriers. Infectious feeding was conducted as previously described [50,51]. Females, 3–5 days old, were starved for 24 h and allowed to feed on blood containing *P. falciparum* gametocytes (from 52.7 to 60.6 gametocytes/ μL) for 35 min. Non-infected salivary glands were obtained by feeding female mosquitoes on the blood from the same donors but heated at 43°C for 12 min for gametocyte inactivation [52]. Unfed and partially fed mosquitoes were removed by aspiration and discarded. Fully engorged females were kept in the insectary until dissections 14 days after the infectious blood meal.

Salivary glands were dissected in buffer containing Urea, 7M; Thiourea, 2M; CHAPS, 4%. Samples were frozen individually until processing.

Protein sample preparation

Infected and non-infected salivary glands were lysed in liquid nitrogen and homogenates were then centrifuged for 20 min at $30,000 \times g$ at 17°C . The supernatants, called salivary gland extracts (SGEs), were collected, purified using a 2D Cleanup Kit (GE Healthcare) and protein concentrations were measured using a Coomassie Plus Protein kit (Pierce). SGEs from about 75 salivary glands were pooled to obtain 15 μg of protein for each batch.

2D Differential Gel Electrophoresis (2D-DIGE)

P. falciparum-infected and non-infected protein samples were compared using the CyDye DIGE Fluors for Ettan DIGE (GE Healthcare, Germany) for four gel replicates.

15 μg of SGE from *P. falciparum*-infected and non-infected samples was labeled with 150 pmol/ μL of either Cy3 or Cy5 following the manufacturer's recommendations. An internal standard comprising 7.5 μg of each SGE was labeled with Cy2. A dye swap was performed to ensure that the modifications observed between the two conditions were not due to different efficiencies in dye labeling. IEF was performed with 11 cm Immobiline DryStrip, pH 3–11 nonlinear (NL) (GE Healthcare, Germany). The run conditions were: current 50 μA per strip; 60 V (step) for 1 h, 1000 V (gradient) for 2 h, 6000 V (gradient) for 2 h and then 6000 V steps up to 30,000 Vh. The second dimension was carried out on 10–20% SDS-PAGE gels (Biorad, Marnes-la-Coquette, France) at 30 V for 20 min and then 200 V until the bromophenol blue front had reached the bottom of the gel. Gels were scanned using a Typhoon 9400 imager (GE Healthcare, Germany). Images were acquired at 100 μm pixel resolution under non-saturating conditions and were analyzed with Progenesis Samespots 3.3 software. Statistical analysis and protein quantification were performed with ANOVA test ($p < 0.005$), which took into account the mean difference and the variance between the infected and non-infected groups. The fold change with a cut-off of 1.4-fold over- and under-expression was used. The statistical power of this study was greater than 0.9.

Protein identification by LC-MS/MS

For the spot excision, gels were stained with the PageBlue Protein Staining Solution (Fermentas).

Trypsin digestion

Enzymatic in-gel digestion was performed according to the Shevchenko modified protocol [53]. Briefly, gel slices were destained by three washes in 50% acetonitrile, 50 mM triethylammonium bicarbonate buffer and incubated

overnight at 25°C (with shaking) with 300 ng trypsin (Gold, Promega, Charbonnières, France) in 100 mM triethylammonium bicarbonate buffer. Tryptic peptides were extracted with 50% acetonitrile and 5% formic acid, and dehydrated in a vacuum centrifuge.

Nano LC-MS/MS analysis

Peptides were solubilized in 2 µL of 0.1% formic acid - 2% acetonitrile and analyzed online by nano-flow HPLC-nanoelectrospray ionization using a LTQ Orbitrap XL mass spectrometer (LTQ Orbitrap XL, Thermo Fisher Scientific, San Jose, CA, USA) coupled with an Ultimate 3000 HPLC (Dionex). Desalting and pre-concentration of samples were performed on-line on a Pepmap® pre-column (0.3 mm × 10 mm). A gradient consisting of 0-40% B for 30 min, 80% B for 15 min (A = 0.1% formic acid, 2% acetonitrile in water; B = 0.1% formic acid in acetonitrile) at 300 nL/min was used to elute peptides from the capillary (0.075 mm × 150 mm) reverse-phase column (Pepmap®, Dionex) fitted with an uncoated silica PicoTip Emitter (New Objective, Woburn, MA, USA). LC-MS/MS experiments comprised cycles of five events; an MS1 scan with Orbitrap mass analysis at 60,000 resolutions followed by collision induced dissociation (CID) of the five most abundant precursors. Fragment ions generated by CID were detected at the linear trap. Normalized collision energy of 35 eV and activation time of 30 ms were used for CID. All Spectra were recorded under positive ion mode using the Xcalibur 2.0.7 software (Thermo Fisher Scientific). Spectra were acquired with the instrument operating in the information-dependent acquisition mode throughout the HPLC gradient. The mass scanning range was m/z 400–2000 and standard mass spectrometric conditions for all experiments were: spray voltage, 2.2 kV; no sheath and auxiliary gas flow; heated capillary temperature, 200°C; capillary voltage, 40 V and tube lens, 120 V. For all full-scan measurements with the Orbitrap detector, a lock-mass ion from ambient air (m/z 445.120024) was used as an internal calibrant as described [54].

All MS/MS spectra were searched for against the Insecta entries of either SwissProt or TrEMBL databases (<http://www.uniprot.org/>; v 2012_07) using the Proteome Discover software v 1.3 (Thermo Fisher Scientific) and Mascot v 2.3 algorithm (<http://www.matrixscience.com/>) with trypsin enzyme specificity and one trypsin missed cleavage. Carbamidomethylation was set as fixed cysteine modification and oxidation was set as variable methionine modification for searches. A peptide mass tolerance of 5 ppm and a fragment mass tolerance of 0.5 Da were allowed for identification.

Management and validation of mass spectrometry data were carried out using Proteome Discoverer software v 1.3 ($p < 0.01$ for 2 peptides or more/protein).

Peptide design

The design of potential immunogenic peptides was investigated using an *in silico* approach. The putative B-cell epitopes were identified with the BcePred [55], ABCpred [56], BepiPred [57] and SVMTrip databases [58]. The sequences were aligned with the Blastp program in the Vectorbase database [59] and the UniProtKB database to compare the peptide sequences with known genomes or EST libraries. The peptides were selected when at least three to four algorithms predicted the same epitopes.

Peptide array

Experiments were performed with EpiFlag® methodology (Innobiochips, Lille, France). Eighteen peptides of 18–27 amino acids were synthesized by solid-phase peptide synthesis with an automated peptide synthesizer (Intavis AG, Köln, Germany) using the Fmoc/tert-butyl strategy on a 20 µmol scale on a Rink-ChemMatrix® (PCAS BioMatrix Inc, Saint-Jean-sur-Richelieu, Quebec, Canada) resin. Following their elongation, peptides were deprotected and cleaved for 3 h at room temperature (RT) using TFA/water/triisopropylsilane/EDT (1850 µL/50 µL/50 µL/50 µL), precipitated in diethyl ether/n-heptane, 1/1 v/v, purified by RP-HPLC on a 120-Å, 5 µm C18 Nucleosil column using a linear water/acetonitrile gradient containing 0.05% TFA by volume (6 mL/min, detection at 215 nm) and lyophilized.

Each peptide characterized by RP-HPLC and MALDI-TOF MS, was dissolved to a final concentration of 0.1 mM in 0.01 M PBS, pH 7.4, and printed on amine-modified glass slides (Arrayit, Sunnyvale, CA, USA) in duplicate.

Peptide arrays were blocked for 1 h at RT with PBS-M (0.01 M PBS, pH7.4, 0.05% Tween 20 and 2.5% non-fat milk). Saturated microarrays were washed with PBS containing 0.05% Tween 20. Human sera from Senegalese children infected by *P. falciparum* or not and exposed to *Anopheles* bites, were diluted 1:10 in PBS-M and incubated overnight at 4°C. Microarrays were then washed three times with PBS containing 0.05% Tween 20. After washing, the microarrays were revealed using a Alexa-Fluor 555-labeled goat polyclonal anti-human IgG antibody (Life Technology, Saint Aubin, France) at 1 µg/mL in PBS-M, for 1 h at RT. Microarrays were washed, rinsed with distilled water and dried. The glass slides were scanned with a TECAN LS-reloaded scanner (Tecan, Männedorf, Switzerland): PMT = 150. Data were extracted using Array-Pro® Analyzer Software.

Results and discussion

Difference in sialome profile between *P. falciparum*-infected and non-infected salivary glands of *An. gambiae*

The salivary glands were dissected 14 days post-infection, i.e. the time period needed for the parasites to reach the


salivary glands. The infectious status of each pair of salivary glands was checked by quantitative PCR [60]. The differential expression of the sialome between *P. falciparum*-infected and non-infected salivary glands of *An. gambiae* was assessed using 2D-DIGE. Overall, four biological replicates of gel were performed. After the ANOVA analysis and adjustment using the FDR approach, 207 spots showed a significant differential profile ($q < 0.01$ and power > 0.9) with a modulation from 1.3- to 8.8-fold. Among them, 128 spots were over-expressed and 79 under-expressed. After colloidal Coomassie blue staining, 43 visible spots could be excised for LC-MS/MS identification (Figure 1A), which represent less than one third of the regulated spots and constitute an additional constraint to the identification of relevant biomarkers. Among them, 24 spots presented a 1.4- to 2.3-fold over-expression in *P. falciparum*-infected salivary glands, whereas 19 spots presented a 1.4- to 2.6-fold under-expression (Figure 1B). These fold changes were in accordance with another study comparing the modification of the *An. gambiae* sialome infected by *P. berghei* using the iTRAQ technology, in which the modulations are within the same range (from 1.5 to 1.95). However, in this previous study, the expression of only five proteins was found to be altered [46]. Another study using the *An. gambiae*-*P. berghei* experimental model has shown that the expression of seven salivary proteins was changed from 3.5- to 12-fold with the 2D-PAGE technique [47]. The larger number of differentially expressed spots in the present experiment may be due to broader protein regulation upon *P. falciparum* infection or alternatively to the different techniques and protocols used between studies.

Identification of overexpressed proteins in *P. falciparum*-infected *An. gambiae* salivary glands

Among the 43 overexpressed spots, two proteins, the ubiquinol cytochrome c reductase iron-sulfur subunit and the gSG6 were found and identified, each in a single spot, as a unique protein (Figure 2 and Table 1).

The ubiquinol-cytochrome c reductase iron-sulfur subunit (Rieske subunit) is an essential component of complex III implicated in the oxidative phosphorylation. The increase in the expression of this enzyme involved in the oxidative phosphorylation has already been observed in the head of *An. gambiae* infected by *P. berghei* [61]. The presence of *P. falciparum* in *An. gambiae* could thus increase oxidative metabolism, which could be a response involved in parasite resistance.

The gSG6 protein was first identified in *An. gambiae* [62] but also found in *An. stephensi* [16] and *An. funestus* [63] and is specifically expressed in salivary glands in female mosquitoes [64]. This protein has not been found in *Culex* [65] and *Aedes* [66,67] mosquitoes, suggesting that it is specific to *Anophelinae* mosquitoes. A study has demonstrated that this protein plays a role in blood feeding [68]. In the present study, the infection of salivary glands of *An. gambiae* by wild *P. falciparum* induced over-expression of the gSG6 protein (+1.8-fold). However, other proteomic studies in murine models of malaria have shown that the gSG6 protein was down-regulated in *An. gambiae* infected by *P. berghei* [46,47]. Discrepancies between studies may result from exposure to different strains of parasites. It is known that a strong relationship between pathogens and their hosts exists, which generates mutual co-evolution and co-adaptation [52,69,70]. In our






Figure 2 Overexpressed proteins in *P. falciparum*-infected *An. gambiae* salivary glands (2D-DIGE gel). Over-expressed protein spots are indicated by number. The pI and molecular weight scales are indicated in the figure.

study, we used the natural model of human malaria, *An. gambiae* and *P. falciparum*, whereas in the other studies *An. gambiae* was infected by a rodent malaria parasite *P. berghei*, whose natural mosquito vector is *An. durenii* [71]. In addition, we used natural isolates of *P. falciparum* and parasite transmission efficiency relies on multiple factors, such as density, sex ratio or genetic complexity [52,72-74]. Interestingly, gene regulation upon *P. falciparum* infection in the mosquito midgut is infection intensity-dependent [52]. In the present study, the gametocyte loads in infected individuals ranged from 52.7 to 60.6 gametocytes/ μ L of blood, which is low compared to parasite densities used with *P. berghei* in laboratory conditions. Differences in parasite densities within salivary glands could also lead to different levels of protein expression in the two parasite species.

In the present study, several proteins belonging to the glutathione S-transferase (GST) family were also up-regulated: GST S1, GST E1, GST D1 isoform D and GST D1 isoform C. GST S1 and GST D1 isoform C were

identified in several closed spots (Figure 2 and Table 1). This could be due to post-translational modifications such as glycosylation, phosphorylation and acetylation. The GST proteins are strongly involved in diverse biological processes in almost organisms such as detoxification of endogenous and xenobiotic compounds as well as in protein transport and protection against oxidative stress [75,76]. This protein family is conserved in the majority of arthropods such as *Ae. aegypti* [77] and *Cx. quiquefasciatus* [78]. The delta and epsilon classes of GST are insect-specific [79]. The GST D1 isoform C and D belongs to the delta class. These genes are rapidly diverging, suggesting a role in the adaptation of insects in different ecological niches and may be involved in the detoxification of environmental xenobiotics. This hypothesis is supported by the implication of this delta class in insecticide resistance [80]. GST E1 belongs to the epsilon class implicated in the detoxification of insecticides and in the resistance to DDT [81-83]. They also have peroxidase activity, which could be involved in

Table 1 Upregulated proteins in *P. falciparum*-infected *An. gambiae* salivary glands

Spot	Accession number (UniProtKB/TrEMBL)	Protein identification	Fold	Molecular mass (kDa)	pI	Mascot score	Sequence coverage (%)
666	P46428_ANOGA	GST S1	2.3	23.2	5.29	7	29.06
	Q9GPL9_ANOGA	GST E1		25.3	5.66	4	17.86
685	P46428_ANOGA	GST S1	2.2	23.2	5.29	9	33.99
695	Q93113_ANOGA	GST D1 iso D	2.0	23.4	6.34	5	25.36
	Q93112_ANOGA	GST D1 iso C		23.8	6.55	3	20.57
927	Q93112_ANOGA	GST D1 iso C	2.3	23.8	6.55	8	36.36
926	Q93112_ANOGA	GST D1 iso C	2.0	23.8	6.55	5	17.70
919	Q7PW11_ANOGA	Ubiquinol cyt c reductase iron sulfur subunit	2.0	28.1	8.53	3	9.43
794	Q9BIH5_ANOGA	gSG6	1.8	13.1	5.49	14	45.22

the protection against the secondary effects of oxidative stress [84]. The GST S1 protein belongs to the sigma class. This class of GST is found in indirect flight muscles, suggesting a structural role. However, it could also protect against the deleterious effects produced by oxidative stress [76]. It has been shown that the malaria infection in mosquito midguts induced an oxidative stress producing reactive oxygen species [85]. Consequently, the increase of GST family proteins probably counteracts the negative effects induced by the infection.

For the other spots, the identification of up- or down-regulated proteins was more complex. Numerous proteins were identified in each spot, which did not allow us to determine which proteins have their expression modified (data not shown). Moreover, several proteins were found both in up- and down-regulated spots, certainly due to post-translational modifications, which made it impossible to conclude whether their expression had been modulated. However, some identified proteins in overexpressed spots involved in a glycolysis pathway (triosephosphate isomerase, fructose biphosphate aldolase, phosphoglycerate mutase and glyceraldehydes-3-phosphate dehydrogenase) were also found upregulated during DENV-3 infection in the cell line of *Ae. albopictus* [86], DENV-2 or CHIKV-infected midgut of *Ae. aegypti* [45] as well as in the *P. berghei*-infected head of *An. gambiae* [61]. In addition, proteins involved in lipid metabolism were found in overexpressed spots, in agreement with a previous transcriptomic study [48]. All these studies strengthen our hypothesis that these identified proteins are probably upregulated. Moreover, these metabolic pathways are involved in energy production, which is in accordance with the over-expression of the ubiquinol-cytochrome c reductase iron-sulfur subunit. *P. falciparum* infection seems to interfere with the metabolic processes of *An. gambiae* salivary glands. This has already been observed during the influenza virus [87] and *Leishmania* [88] infection.

Surprisingly, only seven *P. falciparum* proteins were found in over- and under-expressed spots (Additional file 1). This result could be due to the protein extraction protocol being insufficiently severe to disrupt sporozoites. We can also assume that the amount of salivary gland proteins was much greater resulting in a high salivary gland protein to parasite protein ratio, thus precluding the detection of the *P. falciparum* proteins.

Identification/selection of candidate biomarkers of exposure to *Anopheles* infective bites

The selection of candidates as specific biomarkers for infective bites was based on several criteria: i) over-expression, i.e. overexpressed proteins or proteins found in over-expressed spots with a high percentage of sequence coverage and a high number of identified peptides,

suggesting that they are the major component of the spot; ii) potential antigenicity, i.e. inferred from the presence of a signal peptide in the protein sequence, meaning that they are secreted in the saliva and injected into the human skin during blood feeding and, as a consequence potentially induce an Ab response in humans; and iii) the specificity of proteins to the *Anopheles* genus. As the salivary protein candidates are overexpressed, one hypothesis could be that their antigenicity is increased, only after *P. falciparum* infection, allowing the differentiation between infective and non-infective bites. Among the overexpressed proteins mentioned above, the ubiquinol-cytochrome c reductase Rieske subunit and the GST proteins are common in many organisms and are not secreted proteins. Consequently, they are not suitable candidates for being a specific biomarker to *Anopheles* infected bites.

The gSG6 protein has been previously shown to be a biomarker of exposure to *Anopheles* bites [17-20] and some peptides have also been designed from this protein. Among them, gSG6-P1 and gSG6-P2 peptides were antigenic, but only the gSG6-P1 peptide seemed positively associated with the level of human exposure to *Anopheles* [21], in different exposure settings [22-25]. In the present study, the expression of the gSG6 protein was clearly increased in presence of wild *P. falciparum*. This result suggests that this protein could also be a potential candidate as a biomarker of infective bites. Recent studies strengthen this point by demonstrating that the Ab response to the gSG6 recombinant protein was associated with malaria incidence in Tanzania [20] and that the gSG6-P1 peptide could be an indicator of infection risk during the dry season (very low exposure and transmission) in northern Senegal [89].

Other candidate proteins as biomarkers were selected from some over-expressed spots: gSG1b, TRIO protein, long form D7 and SG5 (Figure 3 and Table 2). The gSG1b and TRIO proteins have already been found to be overexpressed in *P. berghei*-infected salivary glands of *An. gambiae* [47]. This result supports the finding that, in the present study, these proteins, identified among others in overexpressed spots, seem clearly upregulated. The long form D7 and SG5 proteins were selected, although their sequences matched other arthropods but with a low identity. The long form D7 protein presented 35.1% identity with *Ae. Aegypti* ($e = 8e^{-51}$), 34.1% with *Cx. quiquefasciatus* ($e = 5e^{-53}$), 31.3% with *G. morsitans* ($e = 4e^{-04}$), and 27.3% with *Phlebotomus papatasi* ($e = 2e^{-10}$) and *Lutzomia longipalpis* ($e = 3e^{-11}$). The SG5 presented 27.1% identity with *Ae. Aegypti* ($e = 1e^{-30}$) and 24.3% with *Cx. quiquefasciatus* ($e = 1e^{-34}$). The specificity of these proteins as biomarkers of exposure to the *Anopheles* genus will have to be verified and, for example, an animal model of exposure could be used. The Ab response against these proteins, or peptides derived from them, can be assessed in rabbits




Figure 3 Candidate proteins as biomarkers of *Anopheles* infective bites (2D-DIGE gel). Spots containing candidate proteins are indicated by number. The pI and molecular weight scales are indicated in the figure.

exclusively bitten by *Ae. albopictus*, *Ae. aegypti* or *Cx. quinquefasciatus*. However, the use of the peptides from these proteins is another approach and an opportunity to decrease the possible immune cross-reactivity.

Peptide design and antigenicity of selected peptides as potential candidate biomarkers

Aiming to optimize *Anopheles* specificity and to circumvent the limitations in the production of recombinant protein and batch-to-batch variations, peptides from the four previously selected proteins were designed (the gSG1b, long form D7, SG5, TRIO proteins) so as to assess their antigenic properties.

Bioinformatic tools were used to predict potential epitopes for each protein. The comparison of data generated by the four algorithms defined two peptides for gSG1b (gSG1b-P1 and gSG1b-P2), seven peptides for long form D7 (D7-P1 to D7-P7), five peptides for SG5 (SG5-P1 to SG5-P5) and two peptides for the TRIO protein (TRIO-P1 and TRIO-P2), 18–27 amino acid residues long (Table 3).

All these peptides were aligned using the Blastp program in Vectorbase to search for similarities with other hematophagous arthropods and the Blastp program in UniProtKB to search for similarities with human infectious organisms, to avoid immune cross-reactivity. No relevant identity was found, as indicated by the low scores observed (few amino acids (aa) consecutively matched and high e-value, i.e., $e > 0.03$) (Table 4). This analysis showed that all peptides selected possessed a high specificity for the *Anopheles* species.

The antigenicity of these peptides was assessed using an epitope-mapping approach, with serum from children ($n = 42$) known to be exposed to *Anopheles* bites (Figure 4). All peptides appeared to be antigenic, but different levels of antigenicity between them were observed. The D7-P1, SG5-P2, SG5-P3, SG5-P4, SG5-P5, TRIO-P1, TRIO-P2, SG1b-P1 and SG1b-P2 peptides seemed to have a lower antigenicity than the D7-P2, D7-P3, D7-P4, D7-P5, D7-P6, D7-P7 and SG5-P1 peptides. A high antigenicity could be one of the pertinent criteria for the identification of

Table 2 Identification/selection of candidate proteins as biomarkers of *Anopheles* infective bites

Protein identification	Accession number (UniProtKB/TrEMBL)	Spot	Fold	Mascot score	Sequence coverage (%)	Peptide number	Molecular mass (kDa)	pI
gSG6 ^{SP}	Q9BIH5_ANOGA	794	1.8	14	45.22	14	13.1	5.49
gSG1b ^{SP}	Q9BIH6_ANOGA	1197	1.6	59	46.23	59	43.6	7.58
Long form D7 ^{SP}	Q7PJ76_ANOGA	1144	1.4	15	40.19	15	35.6	5.90
SG5 ^{SP}	Q9BIH7_ANOGA	1228	2.0	15	29.22	15	38.2	6.47
		1229	1.6	14	29.52	14		
TRIO protein ^{SP}	Q8WR22_ANOGA	819	1.4	12	31.46	12	43.7	6.46
		1228	2.0	21	36.83	21		
		1229	1.6	15	29.41	15		
		1239	1.4	25	40.15	25		

SP, signal peptide.




Figure 4 IgG Ab response according to the different peptides. The IgG antibody level was evaluated in a sample of children living in Senegal exposed to *Anopheles* bites. Box plots display the median value, 25th and 75th percentiles. Whiskers represent 5 to 95 percentiles and dots the outliers.

Ab responses to infective bites. This strategy could also reduce the heterogeneity of Ab responses observed in this study. Future immunological evaluation of these peptides should be conducted using well documented cohorts either for parasitological and immunological status but also using entomological data to validate this approach.

Conclusion

The present study has provided results on the effect of the presence of the wild *P. falciparum* parasite on the expression of proteins in *An. gambiae* salivary glands. The parasite up- and down-regulates sialome expression, but also seems to induce post-translational modifications. This study and further studies will provide key elements to understand how the insect cells act to protect themselves against infection and how *P. falciparum* manipulates the cellular machinery of the salivary glands and the behavior of *Anopheles* mosquitoes.

In this study, five salivary proteins – gSG6, gSG1b, long form D7, SG5 and TRIO – were selected as potential candidate biomarkers of exposure to *Anopheles* infective bites in order to evaluate the risk of malaria transmission. *Anopheles*-specific and immunogenic peptides were designed from these proteins *in silico*: gSG1b-P1 and gSG1b-P2, D7-P1 to D7-P7, SG5-P1 to SG5-P5, TRIO-P1 and TRIO-P2. Their immunogenicity was tested and validated using blood from children exposed to *Anopheles* bites. These results are the first step toward the development of a biomarker of exposure to *Anopheles* infective bites. This tool is essential to evaluate the malaria transmission in areas of low transmission such as urban settings, highlands and areas where the

P. falciparum transmission has been tackled by malaria control strategies. The next step will be to check whether all these peptides, in addition to gSG6-P1 and gSG6-P2, can differentiate *An. gambiae*-non-infective from -infective bites.

Additional file

Additional file 1: Identification of Plasmodium falciparum proteins.

Abbreviations

Ab: Antibody; WSE: Whole saliva extract; LLIN: Long lasting insecticide-treated nets; IRS: Indoor residual spraying; CHIKV: Chikungunya virus; DENV: Dengue virus; 2D-DIGE: Bidimensional differential gel electrophoresis; SGE: Salivary gland extract; GST: Glutathione S transferase; aa: Amino acid.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

AM, MR, FC, VC, IM, FR and SC designed the study and experiments. AM, MTT, PAA and IM performed the experimental infections. AM and PH carried out the proteomic experiments. MS performed the mass spectrometry analysis. PH and ED assisted in the gel analysis and extraction. AM, PH, MS, ED and SC analyzed the data. AM, SC and FR wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgments

We thank M.N. Lacroix at Laboratoire de lutte contre les insectes nuisibles (Montpellier, France) for the mosquito collection. We are grateful to volunteers from Mfou primary schools and their parents or guardians for participating in this study, to the medical team from the Mfou hospital for assistance in the field, and to the technical staff of the OCEAC for *P. falciparum* infections. We are particularly grateful to Etienne Onana from the OCEAC for mosquito rearing and salivary gland dissections. We acknowledge J.P. Brizard at the UMR 5096 (IRD) for his advice on the proteomic experiments. We thank Linda Northrup for the English revision of the manuscript.

This work was funded by the Institut de Recherche pour le Développement (IRD) and the European Community's Seventh Framework Programme (FP7) (grant agreement No. 242095, EviMalaR). AM was supported by an EviMalaR

scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author details

¹MIVEGEC (UMR IRD224 CNRS 5290 UM1-UM2), Institut de Recherche pour le développement (IRD), 911 avenue Agropolis, Montpellier cedex 5 34394, France. ²CIRAD Département Systèmes Biologiques BIOS UMR 15 CMAEE "Contrôle des Maladies Exotiques et Emergentes", Campus International de Baillarguet, TA A-15/G, Montpellier cedex 5 34398, France. ³Institut de Génétique Fonctionnelle, CNRS UMR 5203, INSERM U661, UM1, UM2, Plate-forme de Protéomique Fonctionnelle CNRS UMS BioCampus 3426, Montpellier 34094, France. ⁴Department of Entomology, Faculty of Agriculture, Kasetsart University, 50 Ngam Wong Wan Rd, Ladyaoow Chatuchak, Bangkok 10900, Thailand. ⁵Laboratoire de Recherche sur le Paludisme, Organisation de Coordination pour la lutte contre les Endémies en Afrique Centrale (OCEAC), Yaoundé BP 288, Cameroun. ⁶MIVEGEC- IRD-CREC, Cotonou 01 BP4414 RP, Bénin.

Received: 24 June 2014 Accepted: 10 December 2014

Published online: 20 December 2014

References

1. WHO: World Malaria Report. 2013.
2. O'Brien C, Henrich PP, Passi N, Fidock DA: Recent clinical and molecular insights into emerging artemisinin resistance in *Plasmodium falciparum*. *Curr Opin Infect Dis* 2011, **24**(6):570–577.
3. Ranson H, N'guessan R, Lines J, Moiroux N, Nkuni Z, Corbel V: Pyrethroid resistance in African anopheline mosquitoes: what are the implications for malaria control? *Trends Parasitol* 2011, **27**(2):91–98.
4. Magesa SM, Aina O, Curtis CF: Detection of pyrethroid resistance in *Anopheles* mosquitoes. *Bull World Health Organ* 1994, **72**(5):737–740.
5. Aikpon R, Agossa F, Ossè R, Ouassou O, Aizoun N, Oké-Agbo F, Akogbeto M: Bendiocarb resistance in *Anopheles gambiae* s.l. populations from Atacora department in Benin, West Africa: a threat for malaria vector control. *Parasit Vectors* 2013, **6**:192.
6. Remoue F, Cisse B, Ba F, Sokhna C, Herve JP, Boulanger D, Simondon F: Evaluation of the antibody response to *Anopheles* salivary antigens as a potential marker of risk of malaria. *Trans R Soc Trop Med Hyg* 2006, **100**(4):363–370.
7. Doucoure S, Mouchet F, Cornelie S, DeHecq JS, Rutee AH, Roca Y, Walter A, Hervé JP, Misse D, Favier F, Gasque P, Remoue F: Evaluation of the human IgG antibody response to *Aedes albopictus* saliva as a new specific biomarker of exposure to vector bites. *PLoS Negl Trop Dis* 2012, **6**(2):e1487.
8. Doucoure S, Mouchet F, Cournil A, Le Goff G, Cornelie S, Roca Y, Giraldez MG, Simon ZB, Loayza R, Misse D, Flores JV, Walter A, Rogier C, Herve JP, Remoue F: Human antibody response to *Aedes aegypti* saliva in an urban population in Bolivia: a new biomarker of exposure to Dengue vector bites. *Am J Trop Med Hyg* 2012, **87**(3):504–510.
9. Remoue F, Alix E, Cornelie S, Sokhna C, Cisse B, Doucoure S, Mouchet F, Boulanger D, Simondon F: IgE and IgG4 antibody responses to *Aedes* saliva in African children. *Acta Trop* 2007, **104**(2–3):108–115.
10. Das MK, Mishra A, Beuria MK, Dash AP: Human natural antibodies to *Culex quinquefasciatus*: age-dependent occurrence. *J Am Mosq Control Assoc* 1991, **7**(2):319–321.
11. Trevejo RT, Reeves WC: Antibody response to *Culex tarsalis* salivary gland antigens among sentinel chickens in California. *Am J Trop Med Hyg* 2005, **72**(4):481–487.
12. Dama E, Cornelie S, Bienvenu Somda M, Camara M, Kambire R, Courtin F, Jamonneau V, Demetere E, Seveno M, Bengaly Z, Solano P, Poinignon A, Remoue F, Belem AMG, Bucheton B: Identification of *Glossina palpalis gambiensis* specific salivary antigens: towards the development of a serologic biomarker of human exposure to tsetse flies in West Africa. *Microbes Infect* 2013, **15**(5):416–427.
13. Poinignon A, Remoue F, Rossignol M, Cornelie S, Courtin D, Grébaud P, Garcia A, Simondon F: Human IgG antibody response to *Glossina* saliva: an epidemiologic marker of exposure to *Glossina* bites. *Am J Trop Med Hyg* 2008, **78**(5):750–753.
14. Clements MF, Gidwani K, Kumar R, Hostomska J, Dinesh DS, Kumar V, Das P, Müller I, Hamilton G, Volfova V, Boelaert M, Das M, Rijal S, Picado A, Volf P, Sundar S, Davies CR, Rogers ME: Measurement of recent exposure to Phlebotomus argentipes, the vector of Indian visceral Leishmaniasis, by using human antibody responses to sand fly saliva. *Am J Trop Med Hyg* 2010, **82**(5):801–807.
15. Martín-Martín I, Molina R, Rohoušová I, Drahota J, Volf P, Jiménez M: High levels of anti-Phlebotomus perniciosus saliva antibodies in different vertebrate hosts from the re-emerging leishmaniasis focus in Madrid. *Spain Vet Parasitol* 2014, **202**(3–4):207–216.
16. Valenzuela JG, Francischetti IM, Pham VM, Garfield MK, Ribeiro JM: Exploring the salivary gland transcriptome and proteome of the *Anopheles stephensi* mosquito. *Insect Biochem Mol Biol* 2003, **33**(7):717–732.
17. Orlandi-Pradines E, Almeras L, Denis de Senneville L, Barbe S, Remoue F, Villard C, Cornelie S, Penhoat K, Pascual A, Bourgouin C, Fontenille D, Bonnet J, Corre-Catelin N, Reiter P, Pages F, Laffite D, Boulanger D, Simondon F, Pradines B, Fusai T, Rogier C: Antibody response against saliva antigens of *Anopheles gambiae* and *Aedes aegypti* in travellers in tropical Africa. *Microbes Infect* 2007, **9**(12–13):1454–1462.
18. Rizzo C, Ronca R, Fiorentino G, Verra F, Mangano V, Poinignon A, Sirima SB, Nebie I, Lombardo F, Remoue F, Coluzzi M, Petrarca V, Modiano D, Arca B: Humoral response to the *Anopheles gambiae* salivary protein gSG6: a serological indicator of exposure to Afrotropical malaria vectors. *PLoS One* 2011, **6**(3):e17980.
19. Rizzo C, Ronca R, Fiorentino G, Mangano VD, Sirima SB, Nebie I, Petrarca V, Modiano D, Arca B: Wide cross-reactivity between *Anopheles gambiae* and *Anopheles funestus* SG6 salivary proteins supports exploitation of gSG6 as a marker of human exposure to major malaria vectors in tropical Africa. *Malar J* 2011, **10**:206.
20. Stone W, Bousema T, Jones S, Gesase S, Hashim R, Gosling R, Carneiro I, Chandramohan D, Theander T, Ronca R, Modiano D, Arca B, Drakeley C: IgG responses to *Anopheles gambiae* salivary antigen gSG6 detect variation in exposure to malaria vectors and disease risk. *PLoS One* 2012, **7**(6):e40170.
21. Poinignon A, Cornelie S, Mestres-Simon M, Lanfrancotti A, Rossignol M, Boulanger D, Cisse B, Sokhna C, Arca B, Simondon F, Remoue F: Novel peptide marker corresponding to salivary protein gSG6 potentially identifies exposure to *Anopheles* bites. *PLoS One* 2008, **3**(6):e2472.
22. Poinignon A, Cornelie S, Ba F, Boulanger D, Sow C, Rossignol M, Sokhna C, Cisse B, Simondon F, Remoue F: Human IgG response to a salivary peptide, gSG6-P1, as a new immuno-epidemiological tool for evaluating low-level exposure to *Anopheles* bites. *Malar J* 2009, **8**:198.
23. Sagna AB, Sarr JB, Gaayeb L, Drame PM, Ndiath MO, Senghor S, Sow CS, Poinignon A, Seck M, Hermann E, Schacht AM, Faye N, Sokhna C, Remoue F, Riveau G: gSG6-P1 salivary biomarker discriminates micro-geographical heterogeneity of human exposure to *Anopheles* bites in low and seasonal malaria areas. *Parasit Vectors* 2013, **6**:68.
24. Badu K, Siangla J, Larbi J, Lawson BW, Afrane Y, Ong'echa J, Remoue F, Zhou G, Githeko AK, Yan G: Variation in exposure to *Anopheles gambiae* salivary gland peptide (gSG6-P1) across different malaria transmission settings in the western Kenya highlands. *Malar J* 2012, **11**:318.
25. Drame PM, Machault V, Diallo A, Cornelie S, Poinignon A, Lalou R, Sembene M, Dos Santos S, Rogier C, Pages F, Le Hesran JY, Remoue F: IgG responses to the gSG6-P1 salivary peptide for evaluating human exposure to *Anopheles* bites in urban areas of Dakar region. *Senegal Malar J* 2012, **11**:72.
26. Poinignon A, Samb B, Doucoure S, Drame PM, Sarr JB, Sow C, Cornelie S, Maiga S, Thiam C, Rogier F, Guindo S, Hermann E, Simondon F, Dia I, Riveau G, Konate L, Remoue F: First attempt to validate the gSG6-P1 salivary peptide as an immuno-epidemiological tool for evaluating human exposure to *Anopheles funestus* bites. *Trop Med Int Health* 2010, **15**(10):1198–1203.
27. Manguin S, Carnevale P, Mouchet J: Biodiversity of Malaria in the World 2008.
28. Drakeley C, Schellenberg D, Kihonda J, Sousa CA, Arez AP, Lopes D, Lines J, Mshinda H, Lengeler C, Armstrong Schellenberg J, Tanner M, Alonso P: An estimation of the entomological inoculation rate for Ifakara: a semi-urban area in a region of intense malaria transmission in Tanzania. *Trop Med Int Health* 2003, **8**(9):767–774.
29. Beier JC, Killeen GF, Githure JI: Short report: entomologic inoculation rates and *Plasmodium falciparum* malaria prevalence in Africa. *Am J Trop Med Hyg* 1999, **61**(1):109–113.
30. Bousema T, Griffin JT, Sauerwein RW, Smith DL, Churcher TS, Takken W, Ghani A, Drakeley C, Gosling R: Hitting hotspots: spatial targeting of malaria for control and elimination. *PLoS Med* 2012, **9**(1):e1001165.

31. Sultan AA, Thathy V, Frevert U, Robson KJ, Crisanti A, Nussenzweig V, Nussenzweig RS, Ménard R: **TRAP is necessary for gliding motility and infectivity of *Plasmodium* sporozoites.** *Cell* 1997, **90**(3):511–522.
32. Brennan JD, Kent M, Dhar R, Fujioka H, Kumar N: **Anopheles gambiae salivary gland proteins as putative targets for blocking transmission of malaria parasites.** *Proc Natl Acad Sci U S A* 2000, **97**(25):13859–13864.
33. Korochkina S, Barreau C, Pradel G, Jeffery E, Li J, Natarajan R, Shabanowitz J, Hunt D, Frevert U, Vernick KD: **A mosquito-specific protein family includes candidate receptors for malaria sporozoite invasion of salivary glands.** *Cell Microbiol* 2006, **8**(1):163–175.
34. Wang J, Zhang Y, Zhao YO, Li MW, Zhang L, Dragovic S, Abraham NM, Fikrig E: **Anopheles gambiae circumsporozoite protein-binding protein facilitates *Plasmodium* infection of mosquito salivary glands.** *J Infect Dis* 2013, **208**(7):1161–1169.
35. Telleria EL, Benoit JB, Zhao X, Savage AF, Regmi S, Alves e Silva TL, O'Neill M, Aksoy S: **Insights into the trypanosome-host interactions revealed through transcriptomic analysis of parasitized tsetse fly salivary glands.** *Plos Negl Trop Dis* 2014, **8**(4):e2649.
36. Ribeiro JM: **Role of saliva in blood-feeding by arthropods.** *Annu Rev Entomol* 1987, **32**:463–478.
37. Rossignol PA, Ribeiro JM, Spielman A: **Increased intradermal probing time in sporozoite-infected mosquitoes.** *Am J Trop Med Hyg* 1984, **33**(1):17–20.
38. McNally KL, Mitzel DN, Anderson JM, Ribeiro JM, Valenzuela JG, Myers TG, Godinez A, Wolfinger JB, Best SM, Bloom ME: **Differential salivary gland transcript expression profile in *Ixodes scapularis* nymphs upon feeding or flavivirus infection.** *Ticks Tick Borne Dis* 2012, **3**(1):18–26.
39. Zivkovic Z, Esteves E, Almazán C, Daffre S, Nijhof AM, Kocan KM, Jongejan F, de la Fuente J: **Differential expression of genes in salivary glands of male *Rhipicephalus* (Boophilus) microplus in response to infection with *Anaplasma marginale*.** *BMC Genomics* 2010, **11**:186.
40. Girard YA, Mayhew GF, Fuchs JF, Li H, Schneider BS, McGee CE, Rocheleau TA, Helmy H, Christensen BM, Higgs S, Bartholomay LC: **Transcriptome changes in *Culex quinquefasciatus* (Diptera: Culicidae) salivary glands during West Nile virus infection.** *J Med Entomol* 2010, **47**(3):421–435.
41. Luplertlop N, Surasombatpattana P, Patramool S, Dumas E, Wasinpiyamongkol L, Saune L, Hamel R, Bernard E, Sereno D, Thomas F, Piquemal D, Yssel H, Briant L, Missé D: **Induction of a peptide with activity against a broad spectrum of pathogens in the *Aedes aegypti* salivary gland, following Infection with Dengue Virus.** *PLoS Pathog* 2011, **7**(1):e1001252.
42. Kariithi HM, Ince IA, Boeren S, Abd-Alla AM, Parker AG, Aksoy S, Vlak JM, Oers MM: **The salivary secretome of the tsetse fly *Glossina pallidipes* (Diptera: Glossinidae) infected by salivary gland hypertrophy virus.** *PLoS Negl Trop Dis* 2011, **5**(11):e1371.
43. Wasinpiyamongkol L, Patramool S, Thongrunkiat S, Maneekan P, Sangmukdanan S, Missé D, Luplertlop N: **Protein expression in the salivary glands of dengue-infected *Aedes aegypti* mosquitoes and blood-feeding success.** *Southeast Asian J Trop Med Public Health* 2012, **43**(6):1346–1357.
44. Zhang M, Zheng X, Wu Y, Gan M, He A, Li Z, Zhang D, Wu X, Zhan X: **Differential proteomics of *Aedes albopictus* salivary gland, midgut and C6/36 cell induced by dengue virus infection.** *Virology* 2013, **444**(1–2):109–118.
45. Tchankouo-Nguetcheu S, Bourguet E, Lenormand P, Rousselle JC, Namane A, Choumet V: **Infection by chikungunya virus modulates the expression of several proteins in *Aedes aegypti* salivary glands.** *Parasit Vectors* 2012, **5**:264.
46. Choumet V, Carmi-Leroy A, Laurent C, Lenormand P, Rousselle JC, Namane A, Roth C, Brey PT: **The salivary glands and saliva of *Anopheles gambiae* as an essential step in the Plasmodium life cycle: a global proteomic study.** *Proteomics* 2007, **7**(18):3384–3394.
47. Zocevic A, Carmi-Leroy A, Sautereau J, d'Alayer J, Lenormand P, Rousselle JC, Namane A, Choumet V: **New markers in *Anopheles gambiae* salivary glands after *Plasmodium berghei* infection.** *Vector Borne Zoonotic Dis* 2013, **13**(2):119–127.
48. Rosinski-Chupin I, Briolay J, Brouilly P, Perrot S, Gomez SM, Cheretemps T, Roth CW, Keime C, Gandrillon O, Couple P, Brey PT: **SAGE analysis of mosquito salivary gland transcriptomes during *Plasmodium* invasion.** *Cell Microbiol* 2007, **9**(3):708–724.
49. Dixit R, Sharma A, Mourya DT, Kamaraju R, Patole MS, Shouche YS: **Salivary gland transcriptome analysis during *Plasmodium* infection in malaria vector *Anopheles stephensi*.** *Int J Infect Dis* 2009, **13**(5):636–646.
50. Harris C, Lambrechts L, Rousset F, Abate L, Nsango SE, Fontenille D, Morlais I, Cohuet A: **Polymorphisms in *Anopheles gambiae* immune genes associated with natural resistance to *Plasmodium falciparum*.** *PLoS Pathog* 2010, **6**(9):e1001112.
51. Mendes AM, Schlegelmilch T, Cohuet A, Awono-Ambene P, De Iorio M, Fontenille D, Morlais I, Christophides GK, Kafatos FC, Vlachou D: **Conserved mosquito/parasite interactions affect development of *Plasmodium falciparum* in Africa.** *PLoS Pathog* 2008, **4**(5):e1000069.
52. Mendes AM, Awono-Ambene PH, Nsango SE, Cohuet A, Fontenille D, Kafatos FC, Christophides GK, Morlais I, Vlachou D: **Infection intensity-dependent responses of *Anopheles gambiae* to the African malaria parasite *Plasmodium falciparum*.** *Infect Immun* 2011, **79**(11):4708–4715.
53. Wilm M, Shevchenko A, Houthaeve T, Breit S, Schweigerer L, Fotsis T, Mann M: **Femtomole sequencing of proteins from polyacrylamide gels by nano-electrospray mass spectrometry.** *Nature* 1996, **379**(6564):466–469.
54. Olsen JV, de Godoy LM, Li G, Macek B, Mortensen P, Pesch R, Makarov A, Lange O, Horning S, Mann M: **Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap.** *Mol Cell Proteomics* 2005, **4**(12):2010–2021.
55. Saha S, Raghava GP: **BcePred: Prediction of Continuous B-Cell Epitopes in Antigenic Sequences Using Physico-chemical Properties.** In: *Artificial immune system*: Springer: Verlag Berlin Heidelberg; 2004: 197–204.
56. Saha S, Raghava GP: **Prediction of continuous B-cell epitopes in an antigen using recurrent neural network.** *Proteins* 2006, **65**(1):40–48.
57. Larsen JE, Lund O, Nielsen M: **Improved method for predicting linear B-cell epitopes.** *Immunome Research* 2006, **2**:2. doi:10.1186/1745-7580-2-2.
58. Yao B, Zhang L, Liang S, Zhang C: **SVMTriP: a method to predict antigenic epitopes using support vector machine to integrate tri-peptide similarity and propensity.** *PLoS One* 2012, **7**(9):e45152.
59. Lawson D, Arensburg P, Atkinson P, Besansky NJ, Bruggner RV, Butler R, Campbell KS, Christophides GK, Christley S, Dialynas E, Emmert D, Hammond M, Hill CA, Kennedy RC, Lobo NF, MacCallum MR, Madey G, Megy K, Redmond S, Russo S, Severson DW, Stinson EO, Topalis P, Zdobnov EM, Birney E, Gelbart WM, Kafatos FC, Louis C, Collins FH: **VectorBase: a home for invertebrate vectors of human pathogens.** *Nucleic Acids Res* 2007, **35**(Database issue):D503–D505.
60. Marie A, Boissière A, Tsapi MT, Poinçon A, Awono-Ambéné PH, Morlais I, Remoue F, Cornélie S: **Evaluation of a real-time quantitative PCR to measure the wild *Plasmodium falciparum* infectivity rate in salivary glands of *Anopheles gambiae*.** *Malar J* 2013, **12**:224.
61. Lefevre T, Thomas F, Schwartz A, Levashina E, Blandin S, Brizard JP, Le Bourlignu L, Demetree E, Renaud F, Biron DG: **Malaria *Plasmodium* agent induces alteration in the head proteome of their *Anopheles* mosquito host.** *Proteomics* 2007, **7**(11):1908–1915.
62. Lanfrancotti A, Lombardo F, Santolamazza F, Veneri M, Castrignano T, Coluzzi M, Arca B: **Novel cDNAs encoding salivary proteins from the malaria vector *Anopheles gambiae*.** *FEBS Lett* 2002, **517**(1–3):67–71.
63. Calvo E, Dao A, Pham VM, Ribeiro JM: **An insight into the salivary gland of *Anopheles funestus* reveals an emerging pattern in anopheline salivary protein families.** *Insect Biochem Mol Biol* 2007, **37**(2):164–175.
64. Francischetti IM, Valenzuela JG, Pham VM, Garfield MK, Ribeiro JM: **Toward a catalog for the transcripts and proteins (sialome) from the salivary gland of the malaria vector *Anopheles gambiae*.** *J Exp Biol* 2002, **205**(Pt 16):2429–2451.
65. Ribeiro JM, Charlab R, Pham VM, Garfield M, Valenzuela JG: **An insight into the salivary transcriptome and proteome of the adult female mosquito *Culex pipiens quinquefasciatus*.** *Insect Biochem Mol Biol* 2004, **34**(6):543–563.
66. Arca B, Lombardo F, Francischetti IM, Pham VM, Mestres-Simon M, Andersen JF, Ribeiro JM: **An insight into the sialome of the adult female mosquito *Aedes albopictus*.** *Insect Biochem Mol Biol* 2007, **37**(2):107–127.
67. Ribeiro JM, Arca B, Lombardo F, Calvo E, Phan VM, Chandra PK, Wikell SK: **An annotated catalogue of salivary gland transcripts in the adult female mosquito, *Aedes aegypti*.** *BMC Genomics* 2007, **8**:6.
68. Lombardo F, Ronca R, Rizzo C, Mestres-Simon M, Lanfrancotti A, Currà C, Fiorentino G, Bourguin C, Ribeiro JM, Petrarca V, Ponzi M, Coluzzi M, Arca B: **The *Anopheles gambiae* salivary protein gSG6: an anopheline-specific protein with a blood-feeding role.** *Insect Biochem Mol Biol* 2009, **39**(7):457–466.
69. Bongfen SE, Laroque A, Berghout J, Gros P: **Genetic and genomic analyses of host-pathogen interactions in malaria.** *Trends Parasitol* 2009, **25**(9):417–422.
70. Harris C, Morlais I, Churcher TS, Awono-Ambene P, Gouagna LC, Dabire RK, Fontenille D, Cohuet A: ***Plasmodium falciparum* produce lower infection intensities in local versus foreign *Anopheles gambiae* populations.** *PLoS One* 2012, **7**(1):e30849.

71. Yoeli M, Most H, Boné G: **The natural history of *Plasmodium berghei* in the field and under experimental conditions.** *Ann Soc Belges Med Trop Parasitol Mycol* 1965, **45**(3):267–272.
72. Bousema T, Dinglasan RR, Morlais I, Gouagna LC, van Warmerdam T, Awono-Ambene PH, Bonnet S, Diallo M, Coulibaly M, Tchuinkam T, Mulder B, Targett G, Drakeley C, Sutherland C, Robert V, Doumbo O, Touré Y, Graves PM, Roeffen W, Sauerwein R, Birkett A, Locke E, Morin M, Wu Y, Churcher TS: **Mosquito feeding assays to determine the infectiousness of naturally infected *Plasmodium falciparum* gametocyte carriers.** *PLoS One* 2012, **7**(8):e42821.
73. Mitri C, Thiery I, Bourgoin C, Paul RE: **Density-dependent impact of the human malaria parasite *Plasmodium falciparum* gametocyte sex ratio on mosquito infection rates.** *Proc Biol Sci* 2009, **276**(1673):3721–3726.
74. Nsango SE, Abate L, Thoma M, Pompon J, Fraiture M, Rademacher A, Berry A, Awono-Ambene PH, Levashina EA, Morlais I: **Genetic clonality of *Plasmodium falciparum* affects the outcome of infection in *Anopheles gambiae*.** *Int J Parasitol* 2012, **42**(6):589–595.
75. Hayes JD, Pulford DJ: **The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance.** *Crit Rev Biochem Mol Biol* 1995, **30**(6):445–600.
76. Singh SP, Coronella JA, Benes H, Cochrane BJ, Zimniak P: **Catalytic function of *Drosophila melanogaster* glutathione S-transferase DmGSTS1-1 (GST-2) in conjugation of lipid peroxidation end products.** *Eur J Biochem* 2001, **268**(10):2912–2923.
77. Lumjuan N, Stevenson BJ, Prapanthadara LA, Somboon P, Brophy PM, Loftus BJ, Severson DW, Ranson H: **The *Aedes aegypti* glutathione transferase family.** *Insect Biochem Mol Biol* 2007, **37**(10):1026–1035.
78. Niranjana Reddy BP, Prasad GB, Raghavendra K: **In silico characterization and comparative genomic analysis of the *Culex quinquefasciatus* glutathione S-transferase (GST) supergene family.** *Parasitol Res* 2011, **109**(4):1165–1177.
79. Fournier D, Bride JM, Poirie M, Bergé JB, Plapp FW: **Insect glutathione S-transferases. Biochemical characteristics of the major forms from houseflies susceptible and resistant to insecticides.** *J Biol Chem* 1992, **267**(3):1840–1845.
80. Vontas JG, Small GJ, Nikou DC, Ranson H, Hemingway J: **Purification, molecular cloning and heterologous expression of a glutathione S-transferase involved in insecticide resistance from the rice brown planthopper, *Nilaparvata lugens*.** *Biochem J* 2002, **362**(Pt 2):329–337.
81. Ding Y, Ortelli F, Rossiter LC, Hemingway J, Ranson H: **The *Anopheles gambiae* glutathione transferase supergene family: annotation, phylogeny and expression profiles.** *BMC Genomics* 2003, **4**(1):35.
82. Lumjuan N, McCarroll L, Prapanthadara LA, Hemingway J, Ranson H: **Elevated activity of an Epsilon class glutathione transferase confers DDT resistance in the dengue vector, *Aedes aegypti*.** *Insect Biochem Mol Biol* 2005, **35**(8):861–871.
83. Ranson H, Rossiter L, Ortelli F, Jensen B, Wang X, Roth CW, Collins FH, Hemingway J: **Identification of a novel class of insect glutathione S-transferases involved in resistance to DDT in the malaria vector *Anopheles gambiae*.** *Biochem J* 2001, **359**(Pt 2):295–304.
84. Ortelli F, Rossiter LC, Vontas J, Ranson H, Hemingway J: **Heterologous expression of four glutathione transferase genes genetically linked to a major insecticide-resistance locus from the malaria vector *Anopheles gambiae*.** *Biochem J* 2003, **373**(Pt 3):957–963.
85. Kumar S, Christophides GK, Cantera R, Charles B, Han YS, Meister S, Dimopoulos G, Kafatos FC, Barillas-Mury C: **The role of reactive oxygen species on *Plasmodium melanotic* encapsulation in *Anopheles gambiae*.** *Proc Natl Acad Sci U S A* 2003, **100**(24):14139–14144.
86. Patramool S, Surasombatpattana P, Lupertlop N, Sévénio M, Choumet V, Thomas F, Missé D: **Proteomic analysis of an *Aedes albopictus* cell line infected with Dengue serotypes 1 and 3 viruses.** *Parasit Vectors* 2011, **4**:138.
87. Ritter JB, Wahl AS, Freund S, Genzel Y, Reichl U: **Metabolic effects of influenza virus infection in cultured animal cells: Intra- and extracellular metabolite profiling.** *BMC Syst Biol* 2010, **4**:61.
88. Rabhi I, Rabhi S, Ben-Othman R, Rasche A, Daskalaki A, Trentin B, Piquemal D, Regnault B, Descoteaux A, Guizani-Tabbane L, Sysco Consortium: **Transcriptomic signature of *Leishmania* infected mice macrophages: a metabolic point of view.** *PLoS Negl Trop Dis* 2012, **6**(8):e1763.
89. Sagna AB, Gaayeb L, Sarr JB, Senghor S, Poinson A, Boutouaba-Combe S, Schacht AM, Hermann E, Faye N, Remoue F, Riveau G: ***Plasmodium falciparum* infection during dry season: IgG responses to *Anopheles gambiae* salivary gSG6-P1 peptide as sensitive biomarker for malaria risk in Northern Senegal.** *Malar J* 2013, **12**(1):301.

doi:10.1186/s13071-014-0599-y

Cite this article as: Marie et al.: *Anopheles gambiae* salivary protein expression modulated by wild *Plasmodium falciparum* infection: highlighting of new antigenic peptides as candidates of *An. gambiae* bites. *Parasites & Vectors* 2014 **7**:599.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

